<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Canadian Pharmacy Blog &#187; Insomnia</title>
	<atom:link href="http://www.canadiannetmall.com/blog/category/insomnia/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.canadiannetmall.com/blog</link>
	<description></description>
	<lastBuildDate>Sat, 07 May 2011 13:51:31 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.1.2</generator>
		<item>
		<title>Eszopiclone for Long-Term Treatment of Insomnia</title>
		<link>http://www.canadiannetmall.com/blog/eszopiclone-for-long-term-treatment-of-insomnia/</link>
		<comments>http://www.canadiannetmall.com/blog/eszopiclone-for-long-term-treatment-of-insomnia/#comments</comments>
		<pubDate>Sat, 13 Nov 2010 20:16:00 +0000</pubDate>
		<dc:creator>Donald</dc:creator>
				<category><![CDATA[Insomnia]]></category>
		<category><![CDATA[Eszopiclone]]></category>
		<category><![CDATA[Long-Term Treatment]]></category>

		<guid isPermaLink="false">http://www.canadiannetmall.com/blog/?p=3992</guid>
		<description><![CDATA[Sepracor, Inc., has announced the FDA&#8217;s approval of its New Drug Application (NDA) for the sleep aid eszopiclone (Generic Lunesta, formerly Estorra™). The recommended dosage for improving sleep onset or maintenance is 2 or 3 mg for adults and 2 mg for adults 65 years of age and older). The 1-mg dose is indicated for [...]]]></description>
		<wfw:commentRss>http://www.canadiannetmall.com/blog/eszopiclone-for-long-term-treatment-of-insomnia/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Asthma Drugs</title>
		<link>http://www.canadiannetmall.com/blog/asthma-drugs/</link>
		<comments>http://www.canadiannetmall.com/blog/asthma-drugs/#comments</comments>
		<pubDate>Thu, 21 Jan 2010 16:34:26 +0000</pubDate>
		<dc:creator>Donald</dc:creator>
				<category><![CDATA[Insomnia]]></category>
		<category><![CDATA[aggression]]></category>
		<category><![CDATA[asthma treatments]]></category>
		<category><![CDATA[label]]></category>
		<category><![CDATA[leukotriene]]></category>
		<category><![CDATA[Montelukast]]></category>
		<category><![CDATA[Prednisone]]></category>
		<category><![CDATA[Singulair]]></category>

		<guid isPermaLink="false">http://www.canadiannetmall.com/blog/?p=2705</guid>
		<description><![CDATA[The FDA plans to update the label of montelukast sodium (Singulair, Merck) zafirlukast (Accolate, AstraZeneca), and zileuton (Zyflo, Cornerstone) with a precaution concerning neuropsychiatric events such as agitation, depression, insomnia, and suicidal thinking. Montelukast drug is indicated for use in children and adults as an asthma and allergy treatment; zafirlukast and zileuton are approved as [...]]]></description>
		<wfw:commentRss>http://www.canadiannetmall.com/blog/asthma-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

